PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Clinical trials for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA explained in plain language.
Never miss a new study
Get alerted when new PAROXYSMAL NOCTURNAL HEMOGLOBINURIA trials appear
Sign up with your email to follow new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Researchers track Long-Term effects of blood disorder treatment
Disease control Not yet recruitingThis study continues to test an investigational injection called LP-005 in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It follows patients who completed an earlier trial to monitor the treatment's long-term safety and how well it controls the dis…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Apr 02, 2026 01:11 UTC
-
New pill trial offers hope for controlling debilitating blood disease
Disease control Not yet recruitingThis study is testing an experimental oral medication called NTQ5082 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disease. It will compare NTQ5082 against an existing standard treatment to see if it's better at raising and maintaining hemogl…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New capsule aims for Long-Term control of rare blood disease
Disease control Not yet recruitingThis study is testing the long-term safety and effectiveness of NTQ5082 capsules for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disorder. It will follow 78 patients who have already benefited from the treatment in earlier studies. The main goa…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Phase: PHASE3 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug under watch: korean study tracks Real-World safety
Disease control Not yet recruitingThis study aims to monitor the safety and effectiveness of the drug Iptacopan (Fabhalta®) in real-world medical settings in Korea. It will follow about 21 adult patients who have been diagnosed with either Paroxysmal Nocturnal Hemoglobinuria (PNH, a rare blood disease) or C3 Glom…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Korean health watchdog launches Post-Approval safety check for rare blood disorder drug
Disease control Not yet recruitingThis study aims to monitor the safety and effectiveness of Danicopan, a medication for a rare blood disease called PNH, in real-world Korean medical settings. It will follow 8 patients already receiving Danicopan alongside their standard treatment to check for side effects and se…
Matched conditions: PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC